Company: MIRA
Filing Date: 2025-09-30
Form Type: 8-K
Source: 0001493152-25-016168
Chunk: 0

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-09-30
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item
1.01. Entry into a Material Definitive Agreement

On
September 29, 2025, MIRA Pharmaceuticals, Inc. (the “ Company”) completed its acquisition of SKNY Pharmaceuticals, Inc. (“ SKNY”)
pursuant to the previously announced merger agreement (the “ Merger Agreement”). At closing, the Company acquired 100% of
SKNY in exchange for restricted shares of the Company’s common stock, par value $0.0001 per share, issued to the shareholders of
SKNY. The number of shares issued was determined based on an exchange ratio derived from independent third-party valuations of both companies.

As
a condition to closing, SKNY contributed $5 million in marketable securities to the Company, further strengthening the Company’s
balance sheet.

The
acquisition of SKNY expands the Company’s pipeline and positions the Company as a multi-program biopharmaceutical developer with
programs addressing high-value therapeutic areas, including:

  Ketamir-2,                                                                                             
  MIRA-55,an oral THC analog with preclinical results in inflammatory pain comparable to morphine,       
  SKNY-1,                                                                                                

The
Company’s Management believes the acquisition of SKNY represents a transformational step in the Company’s growth strategy,
strengthening its financial position and broadening its pipeline of differentiated drug candidates designed to address significant unmet
medical needs.

Item
2.01. Completion of Acquisition or Disposition of Assets